1
|
Nguyen TTK, Pham KY, Yook S. Engineered therapeutic proteins for sustained-release drug delivery systems. Acta Biomater 2023; 171:131-154. [PMID: 37717712 DOI: 10.1016/j.actbio.2023.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 09/04/2023] [Accepted: 09/12/2023] [Indexed: 09/19/2023]
Abstract
Proteins play a vital role in diverse biological processes in the human body, and protein therapeutics have been applied to treat different diseases such as cancers, genetic disorders, autoimmunity, and inflammation. Protein therapeutics have demonstrated their advantages, such as specific pharmaceutical effects, low toxicity, and strong solubility. However, several disadvantages arise in clinical applications, including short half-life, immunogenicity, and low permeation, leading to reduced drug effectiveness. The structure of protein therapeutics can be modified to increase molecular size, leading to prolonged stability and increased plasma half-life. Notably, the controlled-release delivery systems for the sustained release of protein drugs and preserving the stability of cargo proteins are envisioned as a potential approach to overcome these challenges. In this review, we summarize recent research progress related to structural modifications (PEGylation, glycosylation, poly amino acid modification, and molecular biology-based strategies) and promising long-term delivery systems, such as polymer-based systems (injectable gel/implants, microparticles, nanoparticles, micro/nanogels, functional polymers), lipid-based systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers), and inorganic nanoparticles exploited for protein therapeutics. STATEMENT OF SIGNIFICANCE: In this review, we highlight recent advances concerning modifying proteins directly to enhance their stability and functionality and discuss state-of-the-art methods for the delivery and controlled long-term release of active protein therapeutics to their target site. In terms of drug modifications, four widely used strategies, including PEGylation, poly amino acid modification, glycosylation, and genetic, are discussed. As for drug delivery systems, we emphasize recent progress relating to polymer-based systems, lipid-based systems developed, and inorganic nanoparticles for protein sustained-release delivery. This review points out the areas requiring focused research attention before the full potential of protein therapeutics for human health and disease can be realized.
Collapse
Affiliation(s)
- Thoa Thi Kim Nguyen
- College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Dalseo-Gu, Daegu 42601, Republic of Korea
| | - Khang-Yen Pham
- College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Dalseo-Gu, Daegu 42601, Republic of Korea.
| | - Simmyung Yook
- College of Pharmacy, Keimyung University, 1095 Dalgubeol-daero, Dalseo-Gu, Daegu 42601, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea; Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea.
| |
Collapse
|
2
|
Park CS, Kang M, Kim A, Moon C, Kim M, Kim J, Yang S, Jang L, Jang JY, Kim HH. Fragmentation stability and retention time-shift obtained by LC-MS/MS to distinguish sialylated N-glycan linkage isomers in therapeutic glycoproteins. J Pharm Anal 2023; 13:305-314. [PMID: 37102108 PMCID: PMC10124117 DOI: 10.1016/j.jpha.2023.01.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 12/29/2022] [Accepted: 01/14/2023] [Indexed: 01/22/2023] Open
Abstract
Sialylated N-glycan isomers with α2-3 or α2-6 linkage(s) have distinctive roles in glycoproteins, but are difficult to distinguish. Wild-type (WT) and glycoengineered (mutant) therapeutic glycoproteins, cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (CTLA4-Ig), were produced in Chinese hamster ovary cell lines; however, their linkage isomers have not been reported. In this study, N-glycans of CTLA4-Igs were released, labeled with procainamide, and analyzed by liquid chromatography-tandem mass spectrometry (MS/MS) to identify and quantify sialylated N-glycan linkage isomers. The linkage isomers were distinguished by comparison of 1) intensity of the N-acetylglucosamine ion to the sialic acid ion (Ln/Nn) using different fragmentation stability in MS/MS spectra and 2) retention time-shift for a selective m/z value in the extracted ion chromatogram. Each isomer was distinctively identified, and each quantity (>0.1%) was obtained relative to the total N-glycans (100%) for all observed ionization states. Twenty sialylated N-glycan isomers with only α2-3 linkage(s) in WT were identified, and each isomer's sum of quantities was 50.4%. Furthermore, 39 sialylated N-glycan isomers (58.8%) in mono- (3 N-glycans; 0.9%), bi- (18; 48.3%), tri- (14; 8.9%), and tetra- (4; 0.7%) antennary structures of mutant were obtained, which comprised mono- (15 N-glycans; 25.4%), di- (15; 28.4%), tri- (8; 4.8%), and tetra- (1; 0.2%) sialylation, respectively, with only α2-3 (10 N-glycans; 4.8%), both α2-3 and α2-6 (14; 18.4%), and only α2-6 (15; 35.6%) linkage(s). These results are consistent with those for α2-3 neuraminidase-treated N-glycans. This study generated a novel plot of Ln/Nn versus retention time to distinguish sialylated N-glycan linkage isomers in glycoprotein.
Collapse
|
3
|
Cao SJ, Lv ZQ, Guo S, Jiang GP, Liu HL. An update - Prolonging the action of protein and peptide drugs. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2020.102124] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
4
|
Herzig V, Cristofori-Armstrong B, Israel MR, Nixon SA, Vetter I, King GF. Animal toxins - Nature's evolutionary-refined toolkit for basic research and drug discovery. Biochem Pharmacol 2020; 181:114096. [PMID: 32535105 PMCID: PMC7290223 DOI: 10.1016/j.bcp.2020.114096] [Citation(s) in RCA: 81] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 06/06/2020] [Accepted: 06/09/2020] [Indexed: 12/27/2022]
Abstract
Venomous animals have evolved toxins that interfere with specific components of their victim's core physiological systems, thereby causing biological dysfunction that aids in prey capture, defense against predators, or other roles such as intraspecific competition. Many animal lineages evolved venom systems independently, highlighting the success of this strategy. Over the course of evolution, toxins with exceptional specificity and high potency for their intended molecular targets have prevailed, making venoms an invaluable and almost inexhaustible source of bioactive molecules, some of which have found use as pharmacological tools, human therapeutics, and bioinsecticides. Current biomedically-focused research on venoms is directed towards their use in delineating the physiological role of toxin molecular targets such as ion channels and receptors, studying or treating human diseases, targeting vectors of human diseases, and treating microbial and parasitic infections. We provide examples of each of these areas of venom research, highlighting the potential that venom molecules hold for basic research and drug development.
Collapse
Affiliation(s)
- Volker Herzig
- School of Science & Engineering, University of the Sunshine Coast, Sippy Downs, QLD, Australia; Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, Australia.
| | | | - Mathilde R Israel
- Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, Australia
| | - Samantha A Nixon
- Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, Australia
| | - Irina Vetter
- Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, Australia
| | - Glenn F King
- Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD, Australia.
| |
Collapse
|
5
|
Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α. Int J Mol Sci 2020; 21:ijms21114043. [PMID: 32516967 PMCID: PMC7312821 DOI: 10.3390/ijms21114043] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 06/03/2020] [Indexed: 02/07/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. Therefore, exploring effective anticancer agents and their modes of action is essential for the prevention and treatment of HCC. Glycosylation can significantly improve the physicochemical and biological properties of small molecules, such as high solubility, stability increase, and lower toxicity. In the present study, for the first time, we evaluated the anticancer and antiangiogenic activities of α-mangostin-3-O-β-D-2-deoxyglucopyranoside (Man-3DG) and α-mangostin 6-O-β-D-2-deoxyglucopyranoside (Man-6DG), glycosides of α-mangostin, against human HCC cells. Our results demonstrated that Man-3DG and Man-6DG significantly suppressed the growth of three different HCC cells (Hep3B, Huh7, and HepG2) as well as the migration of Hep3B cells. Furthermore, they induced cell cycle arrest in the G0/G1 phases and apoptotic cell death by regulating apoptosis-related proteins of mitochondria in Hep3B cells. Noticeably, Man-3DG and Man-6DG also caused autophagy, while co-treatment of the α-mangostin glycosides with an autophagy inhibitor 3-MA enhanced the inhibitory effect on Hep3B cell growth in comparison to single agent treatment. Moreover, Man-3DG and Man-6DG inhibited the c-Met signaling pathway that plays a critical role in the pathogenesis of HCC. Furthermore, the α-mangostin glycosides decreased Hep3B cell-induced angiogenesis in vitro through the downregulation of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF). Notably, Man-6DG more effectively inhibited the growth, tumorsphere formation, and expression of cancer stemness regulators compared to α-mangostin and Man-3DG in 3D spheroid-cultured Hep3B cells. These findings suggest that the α-mangostin glycosides might be promising anticancer agents for HCC treatment with superior pharmacological properties than the parent molecule α-mangostin.
Collapse
|
6
|
Hofmann S, Bellmann-Sickert K, Beck-Sickinger AG. Chemical modification of neuropeptide Y for human Y1 receptor targeting in health and disease. Biol Chem 2019; 400:299-311. [PMID: 30653463 DOI: 10.1515/hsz-2018-0364] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Accepted: 12/17/2018] [Indexed: 12/14/2022]
Abstract
As a very abundant neuropeptide in the brain and widely distributed peptide hormone in the periphery, neuropeptide Y (NPY) appears to be a multisignaling key peptide. Together with peptide YY, pancreatic polypeptide and the four human G protein-coupled receptor subtypes hY1R, hY2R, hY4R and hY5R it forms the NPY/hYR multiligand/multireceptor system, which is involved in essential physiological processes as well as in human diseases. In particular, NPY-induced hY1R signaling plays a central role in the regulation of food intake and stress response as well as in obesity, mood disorders and cancer. Thus, several hY1R-preferring NPY analogs have been developed as versatile tools to unravel the complex NPY/hY1R signaling in health and disease. Further, these peptides provide basic lead structures for the development of innovative drugs. Here, the current research is summarized focusing on the development of differently sized hY1R-preferring NPY analogs as well as their advances with respect to hY1R profiling, potential therapeutic applications and targeted cancer imaging and therapy. Finally, major limitations and innovative strategies for next generation hY1R-preferring NPY analogs are addressed.
Collapse
Affiliation(s)
- Sven Hofmann
- Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstr. 34, D-04103 Leipzig, Germany
| | - Kathrin Bellmann-Sickert
- Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstr. 34, D-04103 Leipzig, Germany
| | - Annette G Beck-Sickinger
- Institute of Biochemistry, Faculty of Life Sciences, Leipzig University, Brüderstr. 34, D-04103 Leipzig, Germany
| |
Collapse
|
7
|
Frenkel‐Pinter M, Richman M, Belostozky A, Abu‐Mokh A, Gazit E, Rahimipour S, Segal D. Distinct Effects of O‐GlcNAcylation and Phosphorylation of a Tau‐Derived Amyloid Peptide on Aggregation of the Native Peptide. Chemistry 2018; 24:14039-14043. [DOI: 10.1002/chem.201802209] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 06/29/2018] [Indexed: 11/11/2022]
Affiliation(s)
- Moran Frenkel‐Pinter
- Department of Molecular Microbiology and Biotechnology, and the interdisciplinary Sagol School of Neuroscience, George S. Wise Faculty of Life SciencesTel Aviv University Tel Aviv 6997801 Israel
| | - Michal Richman
- Department of ChemistryBar-Ilan University Ramat-Gan 5290002 Israel
| | - Anna Belostozky
- Department of ChemistryBar-Ilan University Ramat-Gan 5290002 Israel
| | - Amjaad Abu‐Mokh
- Department of Molecular Microbiology and Biotechnology, and the interdisciplinary Sagol School of Neuroscience, George S. Wise Faculty of Life SciencesTel Aviv University Tel Aviv 6997801 Israel
| | - Ehud Gazit
- Department of Molecular Microbiology and Biotechnology, and the interdisciplinary Sagol School of Neuroscience, George S. Wise Faculty of Life SciencesTel Aviv University Tel Aviv 6997801 Israel
| | - Shai Rahimipour
- Department of ChemistryBar-Ilan University Ramat-Gan 5290002 Israel
| | - Daniel Segal
- Department of Molecular Microbiology and Biotechnology, and the interdisciplinary Sagol School of Neuroscience, George S. Wise Faculty of Life SciencesTel Aviv University Tel Aviv 6997801 Israel
| |
Collapse
|
8
|
Frenkel-Pinter M, Richman M, Belostozky A, Abu-Mokh A, Gazit E, Rahimipour S, Segal D. Selective Inhibition of Aggregation and Toxicity of a Tau-Derived Peptide using Its Glycosylated Analogues. Chemistry 2016; 22:5945-52. [DOI: 10.1002/chem.201504950] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Indexed: 02/06/2023]
Affiliation(s)
- Moran Frenkel-Pinter
- Department Molecular Microbiology and Biotechnology, and the Interdisciplinary Sagol School of Neurosciences; George S. Wise Faculty of Life Sciences; Tel-Aviv University; Tel Aviv 69978 Israel
| | - Michal Richman
- Department of Chemistry; Bar-Ilan University; Ramat-Gan 5290002 Israel
| | - Anna Belostozky
- Department of Chemistry; Bar-Ilan University; Ramat-Gan 5290002 Israel
| | - Amjaad Abu-Mokh
- Department Molecular Microbiology and Biotechnology, and the Interdisciplinary Sagol School of Neurosciences; George S. Wise Faculty of Life Sciences; Tel-Aviv University; Tel Aviv 69978 Israel
| | - Ehud Gazit
- Department Molecular Microbiology and Biotechnology, and the Interdisciplinary Sagol School of Neurosciences; George S. Wise Faculty of Life Sciences; Tel-Aviv University; Tel Aviv 69978 Israel
| | - Shai Rahimipour
- Department of Chemistry; Bar-Ilan University; Ramat-Gan 5290002 Israel
| | - Daniel Segal
- Department Molecular Microbiology and Biotechnology, and the Interdisciplinary Sagol School of Neurosciences; George S. Wise Faculty of Life Sciences; Tel-Aviv University; Tel Aviv 69978 Israel
| |
Collapse
|
9
|
Heo SC, Kwon YW, Jang IH, Jeong GO, Yoon JW, Kim CD, Kwon SM, Bae YS, Kim JH. WKYMVm-Induced Activation of Formyl Peptide Receptor 2 Stimulates Ischemic Neovasculogenesis by Promoting Homing of Endothelial Colony-Forming Cells. Stem Cells 2014; 32:779-90. [DOI: 10.1002/stem.1578] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2013] [Revised: 09/18/2013] [Accepted: 09/25/2013] [Indexed: 12/24/2022]
Affiliation(s)
- Soon Chul Heo
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Yang Woo Kwon
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Il Ho Jang
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Geun Ok Jeong
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Jung Won Yoon
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Chi Dae Kim
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Pharmacology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Sang Mo Kwon
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
| | - Yoe-Sik Bae
- Department of Biological Sciences; Sungkyunkwan University; Suwon Republic of Korea
| | - Jae Ho Kim
- Medical Research Center for Ischemic Tissue Regeneration; Yangsan Gyeongsangnam-do Republic of Korea
- Department of Physiology; School of Medicine; Pusan National University; Yangsan Gyeongsangnam-do Republic of Korea
- Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital; Yangsan Gyeongsangnam-do Republic of Korea
| |
Collapse
|